Osteoarthritis Pain - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 202 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain - Pipeline Review, H1 2017, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. The predisposing factors are age, joint injury, obesity and heredity. It may be diagnosed by physical examination and MRI and X-ray imaging. The condition may be controlled by weight control, exercise and medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 22, 5, 1, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Osteoarthritis Pain - Overview 8
Osteoarthritis Pain - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 19
Osteoarthritis Pain - Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Osteoarthritis Pain - Companies Involved in Therapeutics Development 30
AbbVie Inc 30
Addex Therapeutics Ltd 30
Allergan Plc 31
Ampio Pharmaceuticals Inc 31
Antibe Therapeutics Inc 32
Aralez Pharmaceuticals Inc 32
Arena Pharmaceuticals Inc 33
Array BioPharma Inc 33
Astellas Pharma Inc 34
Axsome Therapeutics Inc 34
BELLUS Health Inc 35
Boehringer Ingelheim GmbH 35
Cara Therapeutics Inc 36
Chromocell Corp 36
Eli Lilly and Company 37
Elite Pharmaceuticals Inc 37
Eupraxia Pharmaceuticals Inc 38
Flexion Therapeutics Inc 38
Genzyme Corp 39
GlaxoSmithKline Plc 39
Grunenthal GmbH 40
Iroko Pharmaceuticals LLC 40
Marina Biotech Inc 41
Medestea Research & Production SpA 41
MedImmune LLC 42
Merck & Co Inc 42
Nuvo Pharmaceuticals Inc 43
Ono Pharmaceutical Co Ltd 43
Pfizer Inc 44
Phosphagenics Ltd 44
ProteoThera Inc 45
pSivida Corp 45
Purdue Pharma LP 46
Regeneron Pharmaceuticals Inc 46
Rottapharm Biotech Srl 47
Shionogi & Co Ltd 47
Symic Biomedical Inc 48
Taiwan Liposome Company Ltd 48
Vertex Pharmaceuticals Inc 49
Zynerba Pharmaceuticals Inc 49
Osteoarthritis Pain - Drug Profiles 50
(amlodipine besylate + celecoxib) - Drug Profile 50
(celecoxib + lisinopril) - Drug Profile 54
(celecoxib + olmesartan) - Drug Profile 55
(lidocaine hydrochloride + tetracaine) - Drug Profile 56
(naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile 58
2-CCPA - Drug Profile 60
AAT-008 - Drug Profile 61
ADX-71441 - Drug Profile 62
AF-219 - Drug Profile 66
Ampion - Drug Profile 70
APD-371 - Drug Profile 79
AQU-010 - Drug Profile 80
ARRY-954 - Drug Profile 81
AS-288640100 - Drug Profile 82
ASP-7962 - Drug Profile 83
ATB-346 - Drug Profile 84
BI-1026706 - Drug Profile 89
BLU-5937 - Drug Profile 91
cannabidiol - Drug Profile 92
capsaicin - Drug Profile 97
CC-8464 - Drug Profile 100
cebranopadol - Drug Profile 102
celecoxib - Drug Profile 105
CR-4056 - Drug Profile 106
CRB-0089 - Drug Profile 108
dapansutrile - Drug Profile 109
dexamethasone SR - Drug Profile 110
difelikefalin - Drug Profile 111
duloxetine hydrochloride DR - Drug Profile 120
ELS-130 - Drug Profile 123
fasinumab - Drug Profile 124
fluticasone propionate ER - Drug Profile 127
grapiprant - Drug Profile 128
GSK-3196165 - Drug Profile 130
GZ-389988 - Drug Profile 133
ibuprofen - Drug Profile 134
MEDI-7352 - Drug Profile 135
naproxen sodium - Drug Profile 136
NEO-6860 - Drug Profile 138
OLP-1002 - Drug Profile 139
onabotulinumtoxinA - Drug Profile 140
ONO-4474 - Drug Profile 145
oxycodone ER - Drug Profile 146
PA-300 DR - Drug Profile 149
PA-65020 - Drug Profile 150
PRT-1000 - Drug Profile 152
S-120083 - Drug Profile 153
SB-061 - Drug Profile 154
Small Molecules for Osteoarthritis Pain - Drug Profile 156
Small Molecules to Block Calcium Ion Channel for Osteoarthritis Pain - Drug Profile 157
Small Molecules to Block Nav1.7 for Osteoarthritis Pain - Drug Profile 158
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile 159
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile 160
Small Molecules to Inhibit PDE2 for Osteoarthritis Pain - Drug Profile 161
tanezumab - Drug Profile 162
TLC-599 - Drug Profile 166
triamcinolone acetonide ER - Drug Profile 168
VG-201 - Drug Profile 175
VM-902A - Drug Profile 176
VX-150 - Drug Profile 177
WITH-1101 - Drug Profile 178
zoledronic acid - Drug Profile 179
Osteoarthritis Pain - Dormant Projects 182
Osteoarthritis Pain - Discontinued Products 185
Osteoarthritis Pain - Product Development Milestones 187
Featured News & Press Releases 187
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 197
Disclaimer 198

List of Tables

Number of Products under Development for Osteoarthritis Pain, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Osteoarthritis Pain - Pipeline by AbbVie Inc, H1 2017
Osteoarthritis Pain - Pipeline by Addex Therapeutics Ltd, H1 2017
Osteoarthritis Pain - Pipeline by Allergan Plc, H1 2017
Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals Inc, H1 2017
Osteoarthritis Pain - Pipeline by Antibe Therapeutics Inc, H1 2017
Osteoarthritis Pain - Pipeline by Aralez Pharmaceuticals Inc, H1 2017
Osteoarthritis Pain - Pipeline by Arena Pharmaceuticals Inc, H1 2017
Osteoarthritis Pain - Pipeline by Array BioPharma Inc, H1 2017
Osteoarthritis Pain - Pipeline by Astellas Pharma Inc, H1 2017
Osteoarthritis Pain - Pipeline by Axsome Therapeutics Inc, H1 2017
Osteoarthritis Pain - Pipeline by BELLUS Health Inc, H1 2017
Osteoarthritis Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Osteoarthritis Pain - Pipeline by Cara Therapeutics Inc, H1 2017
Osteoarthritis Pain - Pipeline by Chromocell Corp, H1 2017
Osteoarthritis Pain - Pipeline by Eli Lilly and Company, H1 2017
Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals Inc, H1 2017
Osteoarthritis Pain - Pipeline by Eupraxia Pharmaceuticals Inc, H1 2017
Osteoarthritis Pain - Pipeline by Flexion Therapeutics Inc, H1 2017
Osteoarthritis Pain - Pipeline by Genzyme Corp, H1 2017
Osteoarthritis Pain - Pipeline by GlaxoSmithKline Plc, H1 2017
Osteoarthritis Pain - Pipeline by Grunenthal GmbH, H1 2017
Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals LLC, H1 2017
Osteoarthritis Pain - Pipeline by Marina Biotech Inc, H1 2017
Osteoarthritis Pain - Pipeline by Medestea Research & Production SpA, H1 2017
Osteoarthritis Pain - Pipeline by MedImmune LLC, H1 2017
Osteoarthritis Pain - Pipeline by Merck & Co Inc, H1 2017
Osteoarthritis Pain - Pipeline by Nuvo Pharmaceuticals Inc, H1 2017
Osteoarthritis Pain - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Osteoarthritis Pain - Pipeline by Pfizer Inc, H1 2017
Osteoarthritis Pain - Pipeline by Phosphagenics Ltd, H1 2017
Osteoarthritis Pain - Pipeline by ProteoThera Inc, H1 2017
Osteoarthritis Pain - Pipeline by pSivida Corp, H1 2017
Osteoarthritis Pain - Pipeline by Purdue Pharma LP, H1 2017
Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Osteoarthritis Pain - Pipeline by Rottapharm Biotech Srl, H1 2017
Osteoarthritis Pain - Pipeline by Shionogi & Co Ltd, H1 2017
Osteoarthritis Pain - Pipeline by Symic Biomedical Inc, H1 2017
Osteoarthritis Pain - Pipeline by Taiwan Liposome Company Ltd, H1 2017
Osteoarthritis Pain - Pipeline by Vertex Pharmaceuticals Inc, H1 2017
Osteoarthritis Pain - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
Osteoarthritis Pain - Dormant Projects, H1 2017
Osteoarthritis Pain - Dormant Projects, H1 2017 (Contd..1), H1 2017
Osteoarthritis Pain - Dormant Projects, H1 2017 (Contd..2), H1 2017
Osteoarthritis Pain - Discontinued Products, H1 2017
Osteoarthritis Pain - Discontinued Products, H1 2017 (Contd..1), H1 2017